TO OBSERVE THE EFFECT OF AYURVEDIC MEDICINE FOR THE TREATMENT OF BRONCHIAL ASTHMA (TAMAK SHWASA)

CLINICAL EVALUATION OF KANTAKARYAVALEHA AND ELADI GUTIKA IN THE MANAGEMENT OF MILD STABLE BRONCHIAL ASTHMA (TAMAKA SHWASA)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/06/014425

Enrollment

Registered

2018-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Mild Stable Bronchial Asthma (Tamak Shwasa)

Interventions

Intervention1: 1.Kantakaryavaleha (Sharangdhar Samhita, AFI -I, API-II

Vol. IV) : Dose: 10 gms twice daily Dosage form: Avaleha Route of Administration : Oral Time of Administration : Morning & Evening Anupana : Water Duration of therapy:12 weeks Intervention2: 2

Vol. III): Dose: 1 gm thrice daily Dosage form : Tablet Route of Administration : Oral (Chewable) Time of Administration : Morning, Afternoon & Evening Duration of therapy:12 weeks Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex with age between 18 to 60 years. 2. Diagnosed cases of the mild predominant or persistent stable Bronchial Asthma (Tamaka Shwasa) (as per GINA Guideline) 3. FEV1 >80% of the predicted value 4. Patients willing to participate and written consent

Exclusion criteria

Exclusion criteria: 1. Patients with FEV1 2. Patients with Diabetes Mellitus, Chronic Obstructive Pulmonary Disorder (COPD), Cardio vascular diseases, malignancy etc. 3. Patients with unstable Cardiovascular disease 4. Patients suffering from other major systemic illness which may influence the study as per the PI. 5. Patients with LFT, Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT) > 2 times upper normal limit or Serum Creatinine more than the upper limit of normal value. 6. Pregnancy or lactating women.

Design outcomes

Primary

Measure	Time frame
1. Change in Asthma Control Questionnaire (ACQ) 2. Frequency of need for control medicationTimepoint: On baseline, 14th day, 28th day, 42th day, 56th day, 70th day, 84th day and 98th day	—

Secondary

Measure	Time frame
1. Any improvement in FEV1 2. Changes in serum CRP, IgE 3. Frequency of need for rescue medication 4. Any Adverse EventsTimepoint: On baseline, 14th day, 28th day, 42th day, 56th day, 70th day, 84th day and 98th day	—

Countries

India

Contacts

Public ContactDR HARBANS SINGH

CENTRAL AYURVEDA RESEARCH INSTITUTE FOR RESPIRATORY DISORDERS

dr.harbans@rediffmail.com9501248820

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 13, 2026